Psoriasis and beyond: targeting the IL-17 pathway

nature video
11 followers
1 Video View·Sep 5, 2023
Psoriasis is a chronic inflammatory skin disorder that affects about 2-3% of the population. It is triggered by the immune system, and new insights into the immune processes have thrown up a number of exciting drug targets. This Nature Reviews Drug Discovery animation explores how the immune system goes awry in psoriasis and illustrates how agents that target the cytokine interleukin 17, or other players in the same pathway, are being developed into novel therapies for psoriasis.
These scaly red patches are the hallmarks of a common condition called psoriasis.
It's a disease involving immune cells.
This was discovered by chance when, in the late 1970s,
scientists noticed that the immunosuppressive drug cyclosporine can improve the condition.
Skin has three major tissue segments.
The epidermis is composed largely of specialised cells called keratinocytes.
These originate from a single layer of basal keratinocytes,
which divide continuously and give rise to cells that migrate towards the skin's surface.
During this process, they progressively differentiate into corneocytes,
which form a protective barrier.
Below the epidermis is the dermis.
Here, cells called fibroblasts secrete fibres that form a dense extracellular matrix.
This layer also contains hair follicles, sweat glands,
sebaceous glands and blood capillaries, as well as lymphatic vessels.
These are a major conduit for immune cells such as macrophages, dendritic cells and T-cells.
Dendritic cells can capture foreign antigen and present it to T-cells.
T-cells are immune effector cells.
They can broadly be divided into cytotoxic T-cells, which directly kill infected cells,
and T-helper cells that play a key role in orchestrating overall immune responses.
In many ways, the immune pathways that become activated in psoriasis
are amplifications of the immune activity of normal skin.
However, the trigger for this inflammatory disease is unknown.
Current models propose that dendritic cells sense stressed keratinocytes and invading microorganisms
and start to respond by producing signalling molecules known as cytokines.
These activate T-cells and other immune cells, which in turn produce their own cytokines.
Those signals stimulate keratinocytes to proliferate and to secrete further mediators
and create a vicious cycle of inflammatory responses.
Overall, this results in an accumulation of immune cells
and the formation of a thickened, inflamed epidermis.
Several biologic drugs have been developed to target inflammatory mediators in psoriasis.
The most widely used agents for severe psoriasis dampen down the cytokine TNF-alpha.
But that treatment doesn't work for everyone.
Up to a third of patients ultimately do not respond.
However, in the past decade, insights into T-cell biology have uncovered some promising new drug targets.
Traditionally, T-helper cells have been classified into two subsets.
T-helper 1 cells, which are pro-inflammatory, and T-helper 2 cells, which are anti-inflammatory.
However, the picture has become much more complicated with the identification of many other subsets.
Which subset a T-helper cell will belong to depends on the cytokines it encounters
when it first interacts with a dendritic cell.
Each subset can then be told apart because they secrete characteristic cytokines.
In the context of psoriasis and inflammation, T-helper 17 cells have attracted particular attention.
They're part of a group known as type 17 cells because they produce the cytokine IL-17.
This cytokine can promote chronic inflammation and tissue destruction.
In psoriasis, dendritic cells produce two important cytokines, IL-12 and IL-23.
IL-12 induces the differentiation of T-helper 1 cells, which produce the cytokines interferon-gamma and TNF-alpha.
IL-23, in turn, induces T-helper 17 cells, which make IL-17 and other pro-inflammatory cytokines.
Scientists are now developing a number of biologic drugs that are targeted at IL-17
and other elements of the IL-17 signalling cascade.
Interesting targets include IL-23, a shared subunit of both IL-12 and IL-23,
the different isoforms of IL-17 and the IL-17 receptor,
as well as a protein that's required for the production of IL-17.
As IL-17 functions mainly locally in the skin and in mucosal tissues,
such agents may have fewer side effects than current drugs which act systemically,
and they might be effective in patients who don't respond to therapies that target TNF-alpha.
The first of these agents has already been approved for psoriasis,
and others have shown promising results in clinical trials.
Many of these are also in development for other inflammatory diseases,
including rheumatoid arthritis, asthma and colitis,
making the IL-17 cascade one of the hottest targets for inflammatory diseases.
